Daniel Siniawski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Siniawski has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Walter Masson
Department of Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
5 shared publications - Leandro Barbagelata
Servicio de Cardiología, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
4 shared publications - Gerardo Masson
Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, Argentina. Servicio de Cardiología, Hospital Italiano de Buenos Aires. Servicio de Cardiología, Instituto Cardiovascular San Isidro
2 shared publications - Melina S. Huerin
Instituto Cardiovascular Lezica
2 shared publications - Santiago Lynch
Consejo de cardiometabolismo SAC
2 shared publications - Eliana Kerschner
Servicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
1 shared publication
Latest Publications
- Open Access
- 31 October 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Impacto de la optimización del tratamiento hipolipemiante en el riesgo cardiovascular residual
Background: The SMART-REACH model predicts the risk or recurrent cardiovascular events. Objectives: The objectives of this study were: a) to evaluate the residual cardiovascular risk in a secondary prevention population with low-density lipoprotein cholesterol (LDL-C) levels above the recommended goal, using a simulation model; and b) to determine the impact of optimizing lipid-lowering therapies in terms of residual cardiovascular risk reduction. Methods: We conducted a cross-sectional, descriptive and multicenter study. Patients with a history of cardiovascular disease and LDL-C ≥ 55 mg/dL were consecutively included. The 10-year and lifetime risk of recurrent events (myocardial infarction, stroke, or vascular death) were estimated using the SMART-REACH model. By means of a simulation, lipid-lowering treatment was optimized for each patient [using statins, ezetimibe and/or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)], with estimation of LDL-C reduction, checking if lipid-lowering goal was achieved and calculating the reduction in cardiovascular risk and the corresponding number needed to treat (NNT). Results: The cohort was made up of 187 patients; mean age was 67.9 ± 9.3 years and 72.7% were men. The calculated 10-year and lifetime residual risks were 37.1 ± 14.7% and 60.3 ± 10.7%, respectively. Overall, treatment was optimized with a single pharmaco logical strategy with statins, ezetimibe or PCSK9i inhibitor in 38.5%, 11.5% and 5.5% of the population, respectively. Optimization based on two treatments was performed in 27.5% (statins + ezetimibe), 7.7% (statins + PCSK9i) and 1.1% (ezetimibe + PCSK9i ) of the cases. In 15 patients, treatment was optimized when the three drugs (statins + ezetimibe + PCSK9i) were considered. Overall, 53.9% and 62.9% of the actions implemented to optimize treatment showed a 10-year or lifetime NNT < 30 to prevent an event, respectively. Conclusion: In this study, patients with a history of cardiovascular disease who do not reach LDL-C goal showed significant residual cardiovascular risk. The simulation model showed a significant margin for optimizing treatment, with a marked reduction in residual cardiovascular risk. Keywords: Residual cardiovascular risk - Cholesterol LDL - Hydroxymethylglutaryl-CoA reductase inhibitors - Ezetimibe - PCSK9 inhibitors. How to cite this article Masson W, Barbagelata L. Masson G, Lynch S, Huerin M, Siniawski D. Impact of Optimizing Lipid-Lowering Therapy on Residual Cardiovascular Risk. Rev Argent Cardiol 2023;91:309-16. http://dx.doi.org/10.7775/rac.v91.i5.20666
- 31 October 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessImpacto de la optimización del tratamiento hipolipemiante en el riesgo cardiovascular residual
Background: The SMART-REACH model predicts the risk or recurrent cardiovascular events. Objectives: The objectives of this study were: a) to evaluate the residual cardiovascular risk in a secondary prevention population with low-density lipoprotein cholesterol (LDL-C) levels above the recommended goal, using a simulation model; and b) to determine the impact of optimizing lipid-lowering therapies in terms of residual cardiovascular risk reduction. Methods: We conducted a cross-sectional, descriptive and multicenter study. Patients with a history of cardiovascular disease and LDL-C ≥ 55 mg/dL were consecutively included. The 10-year and lifetime risk of recurrent events (myocardial infarction, stroke, or vascular death) were estimated using the SMART-REACH model. By means of a simulation, lipid-lowering treatment was optimized for each patient [using statins, ezetimibe and/or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)], with estimation of LDL-C reduction, checking if lipid-lowering goal was achieved and calculating the reduction in cardiovascular risk and the corresponding number needed to treat (NNT). Results: The cohort was made up of 187 patients; mean age was 67.9 ± 9.3 years and 72.7% were men. The calculated 10-year and lifetime residual risks were 37.1 ± 14.7% and 60.3 ± 10.7%, respectively. Overall, treatment was optimized with a single pharmaco logical strategy with statins, ezetimibe or PCSK9i inhibitor in 38.5%, 11.5% and 5.5% of the population, respectively. Optimization based on two treatments was performed in 27.5% (statins + ezetimibe), 7.7% (statins + PCSK9i) and 1.1% (ezetimibe + PCSK9i ) of the cases. In 15 patients, treatment was optimized when the three drugs (statins + ezetimibe + PCSK9i) were considered. Overall, 53.9% and 62.9% of the actions implemented to optimize treatment showed a 10-year or lifetime NNT < 30 to prevent an event, respectively. Conclusion: In this study, patients with a history of cardiovascular disease who do not reach LDL-C goal showed significant residual cardiovascular risk. The simulation model showed a significant margin for optimizing treatment, with a marked reduction in residual cardiovascular risk. Keywords: Residual cardiovascular risk - Cholesterol LDL - Hydroxymethylglutaryl-CoA reductase inhibitors - Ezetimibe - PCSK9 inhibitors. How to cite this article Masson W, Barbagelata L. Masson G, Lynch S, Huerin M, Siniawski D. Impact of Optimizing Lipid-Lowering Therapy on Residual Cardiovascular Risk. Rev Argent Cardiol 2023;91:309-16. http://dx.doi.org/10.7775/rac.v91.i5.20666
- Open Access
- 31 October 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Impacto de la optimización del tratamiento hipolipemiante en el riesgo cardiovascular residual
Background: The SMART-REACH model predicts the risk or recurrent cardiovascular events. Objectives: The objectives of this study were: a) to evaluate the residual cardiovascular risk in a secondary prevention population with low-density lipoprotein cholesterol (LDL-C) levels above the recommended goal, using a simulation model; and b) to determine the impact of optimizing lipid-lowering therapies in terms of residual cardiovascular risk reduction. Methods: We conducted a cross-sectional, descriptive and multicenter study. Patients with a history of cardiovascular disease and LDL-C ≥ 55 mg/dL were consecutively included. The 10-year and lifetime risk of recurrent events (myocardial infarction, stroke, or vascular death) were estimated using the SMART-REACH model. By means of a simulation, lipid-lowering treatment was optimized for each patient [using statins, ezetimibe and/or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)], with estimation of LDL-C reduction, checking if lipid-lowering goal was achieved and calculating the reduction in cardiovascular risk and the corresponding number needed to treat (NNT). Results: The cohort was made up of 187 patients; mean age was 67.9 ± 9.3 years and 72.7% were men. The calculated 10-year and lifetime residual risks were 37.1 ± 14.7% and 60.3 ± 10.7%, respectively. Overall, treatment was optimized with a single pharmaco logical strategy with statins, ezetimibe or PCSK9i inhibitor in 38.5%, 11.5% and 5.5% of the population, respectively. Optimization based on two treatments was performed in 27.5% (statins + ezetimibe), 7.7% (statins + PCSK9i) and 1.1% (ezetimibe + PCSK9i ) of the cases. In 15 patients, treatment was optimized when the three drugs (statins + ezetimibe + PCSK9i) were considered. Overall, 53.9% and 62.9% of the actions implemented to optimize treatment showed a 10-year or lifetime NNT < 30 to prevent an event, respectively. Conclusion: In this study, patients with a history of cardiovascular disease who do not reach LDL-C goal showed significant residual cardiovascular risk. The simulation model showed a significant margin for optimizing treatment, with a marked reduction in residual cardiovascular risk. Keywords: Residual cardiovascular risk - Cholesterol LDL - Hydroxymethylglutaryl-CoA reductase inhibitors - Ezetimibe - PCSK9 inhibitors. How to cite this article Masson W, Barbagelata L. Masson G, Lynch S, Huerin M, Siniawski D. Impact of Optimizing Lipid-Lowering Therapy on Residual Cardiovascular Risk. Rev Argent Cardiol 2023;91:309-16. http://dx.doi.org/10.7775/rac.v91.i5.20666
- 31 October 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
Open AccessImpacto de la optimización del tratamiento hipolipemiante en el riesgo cardiovascular residual
Background: The SMART-REACH model predicts the risk or recurrent cardiovascular events. Objectives: The objectives of this study were: a) to evaluate the residual cardiovascular risk in a secondary prevention population with low-density lipoprotein cholesterol (LDL-C) levels above the recommended goal, using a simulation model; and b) to determine the impact of optimizing lipid-lowering therapies in terms of residual cardiovascular risk reduction. Methods: We conducted a cross-sectional, descriptive and multicenter study. Patients with a history of cardiovascular disease and LDL-C ≥ 55 mg/dL were consecutively included. The 10-year and lifetime risk of recurrent events (myocardial infarction, stroke, or vascular death) were estimated using the SMART-REACH model. By means of a simulation, lipid-lowering treatment was optimized for each patient [using statins, ezetimibe and/or proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)], with estimation of LDL-C reduction, checking if lipid-lowering goal was achieved and calculating the reduction in cardiovascular risk and the corresponding number needed to treat (NNT). Results: The cohort was made up of 187 patients; mean age was 67.9 ± 9.3 years and 72.7% were men. The calculated 10-year and lifetime residual risks were 37.1 ± 14.7% and 60.3 ± 10.7%, respectively. Overall, treatment was optimized with a single pharmaco logical strategy with statins, ezetimibe or PCSK9i inhibitor in 38.5%, 11.5% and 5.5% of the population, respectively. Optimization based on two treatments was performed in 27.5% (statins + ezetimibe), 7.7% (statins + PCSK9i) and 1.1% (ezetimibe + PCSK9i ) of the cases. In 15 patients, treatment was optimized when the three drugs (statins + ezetimibe + PCSK9i) were considered. Overall, 53.9% and 62.9% of the actions implemented to optimize treatment showed a 10-year or lifetime NNT < 30 to prevent an event, respectively. Conclusion: In this study, patients with a history of cardiovascular disease who do not reach LDL-C goal showed significant residual cardiovascular risk. The simulation model showed a significant margin for optimizing treatment, with a marked reduction in residual cardiovascular risk. Keywords: Residual cardiovascular risk - Cholesterol LDL - Hydroxymethylglutaryl-CoA reductase inhibitors - Ezetimibe - PCSK9 inhibitors. How to cite this article Masson W, Barbagelata L. Masson G, Lynch S, Huerin M, Siniawski D. Impact of Optimizing Lipid-Lowering Therapy on Residual Cardiovascular Risk. Rev Argent Cardiol 2023;91:309-16. http://dx.doi.org/10.7775/rac.v91.i5.20666
- Open Access
- 15 May 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
- Vol. 91 (2) , 109-116
Limitaciones de los puntajes de riesgo cardiovascular en prevención primaria ¿Una oportunidad para los moduladores de riesgo?
Introducción: Los puntajes de riesgo cardiovascular tienen limitaciones relacionadas con la calibración, la discriminación y la baja sensibilidad. Se han identificado diferentes “moduladores de riesgo” que permiten mejorar la estratificación del riesgo cardiovascular: placa aterosclerótica carotídea (PAC), puntaje de calcio arterial coronario (pCAC) y lipoproteína(a) [Lp(a)]. Objetivos: 1) determinar la prevalencia de los moduladores de riesgo citados en una población en prevención primaria; 2) determinar la concordancia entre los 2 métodos de detección de aterosclerosis subclínica; 3) establecer qué proporción de pacientes deberían recibir estatinas inicialmente, según su puntaje de riesgo, y posteriormente con el conocimiento de los moduladores de riesgo.Material y métodos: Se incluyeron individuos de 18 a 79 años, que asistieron para una evaluación de riesgo cardiovascular y que no estaban recibiendo tratamiento hipolipemiante. Se calculó el puntaje de riesgo (ASCVD Risk Estimator) en cada paciente. Se evaluó la presencia de PAC, el pCAC y el nivel plasmático de Lp(a). Resultados: Se incluyeron 348 pacientes (edad media 55,6 ± 12,2 años, 45,4% hombres). En la población total, 29,8%, 36,8% y 53,2% de los pacientes mostraron un valor de Lp(a) ≥ 50 mg/dL, PAC o un pCAC > 0, respectivamente. La prevalencia de PAC y pCAC fue progresivamente mayor según la categoría de riesgo cardiovascular; sin embargo, la proporción de sujetos de bajo riesgo que tenían moduladores de riesgo fue considerable (Lp(a) ≥ 50 mg/dl: 25,7%; PAC: 22%; pCAC > 0: 33%). En los 60 individuos menores de 45 años la prevalencia de pCAC > 0 y PAC fue de 18,3% y 10%, respectivamente. La concordancia entre los dos métodos para determinar la presencia de ateromatosis subclínica fue discreta (kappa 0,33). La indicación del tratamiento con estatinas aumentó un 31,6% luego de evaluar la presencia de moduladores.Conclusión: La presencia de moduladores de riesgo fue frecuente en esta población en prevención primaria, incluso en sujetos de bajo riesgo o menores de 45 años. La detección de moduladores de riesgo podría mejorar la estratificación inicial y llevar a reconsiderar el tratamiento con estatinas. Citar como: Siniawski DA, Masson WA, Barbagelata L. Limitaciones de los puntajes de riesgo cardiovascular en prevención primaria ¿Una oportunidad para los moduladores de riesgo? Rev Argent Cardiol 2023;91:109-16. https://doi.org/10.7775/rac.es.v91.i2.20609
- 15 May 2023
- Published by Revista Argentina de Cardiologia in Revista Argentina de Cardiologia
- Vol. 91 (2) , 109-116
Open AccessLimitaciones de los puntajes de riesgo cardiovascular en prevención primaria ¿Una oportunidad para los moduladores de riesgo?
Introducción: Los puntajes de riesgo cardiovascular tienen limitaciones relacionadas con la calibración, la discriminación y la baja sensibilidad. Se han identificado diferentes “moduladores de riesgo” que permiten mejorar la estratificación del riesgo cardiovascular: placa aterosclerótica carotídea (PAC), puntaje de calcio arterial coronario (pCAC) y lipoproteína(a) [Lp(a)]. Objetivos: 1) determinar la prevalencia de los moduladores de riesgo citados en una población en prevención primaria; 2) determinar la concordancia entre los 2 métodos de detección de aterosclerosis subclínica; 3) establecer qué proporción de pacientes deberían recibir estatinas inicialmente, según su puntaje de riesgo, y posteriormente con el conocimiento de los moduladores de riesgo.Material y métodos: Se incluyeron individuos de 18 a 79 años, que asistieron para una evaluación de riesgo cardiovascular y que no estaban recibiendo tratamiento hipolipemiante. Se calculó el puntaje de riesgo (ASCVD Risk Estimator) en cada paciente. Se evaluó la presencia de PAC, el pCAC y el nivel plasmático de Lp(a). Resultados: Se incluyeron 348 pacientes (edad media 55,6 ± 12,2 años, 45,4% hombres). En la población total, 29,8%, 36,8% y 53,2% de los pacientes mostraron un valor de Lp(a) ≥ 50 mg/dL, PAC o un pCAC > 0, respectivamente. La prevalencia de PAC y pCAC fue progresivamente mayor según la categoría de riesgo cardiovascular; sin embargo, la proporción de sujetos de bajo riesgo que tenían moduladores de riesgo fue considerable (Lp(a) ≥ 50 mg/dl: 25,7%; PAC: 22%; pCAC > 0: 33%). En los 60 individuos menores de 45 años la prevalencia de pCAC > 0 y PAC fue de 18,3% y 10%, respectivamente. La concordancia entre los dos métodos para determinar la presencia de ateromatosis subclínica fue discreta (kappa 0,33). La indicación del tratamiento con estatinas aumentó un 31,6% luego de evaluar la presencia de moduladores.Conclusión: La presencia de moduladores de riesgo fue frecuente en esta población en prevención primaria, incluso en sujetos de bajo riesgo o menores de 45 años. La detección de moduladores de riesgo podría mejorar la estratificación inicial y llevar a reconsiderar el tratamiento con estatinas. Citar como: Siniawski DA, Masson WA, Barbagelata L. Limitaciones de los puntajes de riesgo cardiovascular en prevención primaria ¿Una oportunidad para los moduladores de riesgo? Rev Argent Cardiol 2023;91:109-16. https://doi.org/10.7775/rac.es.v91.i2.20609
- 1 April 2023
- Published by Revista Argentina de Cardiologia
- Vol. 91 (2) , 102-109
Limitations of Cardiovascular Risk Scores in Primary Prevention. An Opportunity for Risk Modulators?
Background: Cardiovascular risk scores have limitations related to calibration, discrimination, and low sensitivity. Different "risk modulators" have been identified to improve cardiovascular risk stratification: carotid atherosclerotic plaque (CAP), coronary artery calcium (CAC) score and lipoprotein(a) [Lp(a)]. Objectives: The aims of this study were: 1) to determine the prevalence of risk modulators mentioned in a primary prevention population; 2) determine the concordance between the 2 methods of detecting subclinical atherosclerosis; and 3) establish which proportion of patients should receive statins according to the initial risk stratification and after being recategorized by screening for risk modulators. Methods: Individuals aged 18 to 79 years who consulted for cardiovascular risk assessment and who were not receiving lipid-lowering treatment were included. The risk score was calculated in each patient using ASCVD Risk Estimator. The presence of CAP, CAC score and Lp(a) level were evaluated. Results: The cohort was made up of 348 patients; mean age was 55.6 ± 12.2 years and 45.4% were men. In the total population, 29.8%, 36.8%, and 53.2% of patients showed Lp(a) value ≥ 50 mg/dL, CAP, or a CAC score > 0, respectively. The prevalence of CAP and CAC score was progressively higher according to the cardiovascular risk category; however, the proportion of low-risk subjects who had risk modulators was considerable (Lp(a) ≥ 50 mg/dl: 25.7%; CAP: 22%; CAC score > 0: 33%). In the 60 subjects 0 and CAP was 18.3% and 10%, respectively. The agreement between the two methods for quantifying subclinical atheromatosis was fair (kappa= 0.33). The indication for statin treatment increased by 31.6% after evaluating the presence of modulators. Conclusion: The presence of risk modulators was common in this population in primary prevention, even in low-risk subjects or <45 years. Detection of risk modulators could improve initial stratification and lead to reconsideration of statin treatment.
- 1 April 2023
- Published by Revista Argentina de Cardiologia
- Vol. 91 (2) , 102-109
Limitations of Cardiovascular Risk Scores in Primary Prevention. An Opportunity for Risk Modulators?
Background: Cardiovascular risk scores have limitations related to calibration, discrimination, and low sensitivity. Different "risk modulators" have been identified to improve cardiovascular risk stratification: carotid atherosclerotic plaque (CAP), coronary artery calcium (CAC) score and lipoprotein(a) [Lp(a)]. Objectives: The aims of this study were: 1) to determine the prevalence of risk modulators mentioned in a primary prevention population; 2) determine the concordance between the 2 methods of detecting subclinical atherosclerosis; and 3) establish which proportion of patients should receive statins according to the initial risk stratification and after being recategorized by screening for risk modulators. Methods: Individuals aged 18 to 79 years who consulted for cardiovascular risk assessment and who were not receiving lipid-lowering treatment were included. The risk score was calculated in each patient using ASCVD Risk Estimator. The presence of CAP, CAC score and Lp(a) level were evaluated. Results: The cohort was made up of 348 patients; mean age was 55.6 ± 12.2 years and 45.4% were men. In the total population, 29.8%, 36.8%, and 53.2% of patients showed Lp(a) value ≥ 50 mg/dL, CAP, or a CAC score > 0, respectively. The prevalence of CAP and CAC score was progressively higher according to the cardiovascular risk category; however, the proportion of low-risk subjects who had risk modulators was considerable (Lp(a) ≥ 50 mg/dl: 25.7%; CAP: 22%; CAC score > 0: 33%). In the 60 subjects 0 and CAP was 18.3% and 10%, respectively. The agreement between the two methods for quantifying subclinical atheromatosis was fair (kappa= 0.33). The indication for statin treatment increased by 31.6% after evaluating the presence of modulators. Conclusion: The presence of risk modulators was common in this population in primary prevention, even in low-risk subjects or <45 years. Detection of risk modulators could improve initial stratification and lead to reconsideration of statin treatment.
- Open Access
- 7 February 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (3) , 408-415
Screening program for familial hyperchylomicronemia syndrome detection: Experience of a university health system
Objective: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. Materials and methods: A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages: [...] ABSTRACT Objective: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. Materials and methods: A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages:
- 7 February 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (3) , 408-415
Open AccessScreening program for familial hyperchylomicronemia syndrome detection: Experience of a university health system
Objective: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. Materials and methods: A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages: [...] ABSTRACT Objective: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by mutations related to chylomicron metabolism. The objective of this study is to show the development and results of a screening program for FCS in Argentina. Materials and methods: A cross-sectional study was performed. All patients > 18 years with a triglyceride level ≥ 1,000 mg/dL in the period from January 1, 2017 to December 31, 2021 were included. The program was developed in three stages: